File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/jmv.29313
- Scopus: eid_2-s2.0-85179735602
- PMID: 38100626
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination
Title | Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination |
---|---|
Authors | |
Keywords | ACE2 autoantibody COVID-19 COVID-19 vaccine enzymatic immunoassay SARS-CoV-2 |
Issue Date | 15-Dec-2023 |
Publisher | Wiley Periodicals |
Citation | Journal of Medical Virology, 2023, v. 95, n. 12 How to Cite? |
Abstract | Autoantibodies against angiotensin-converting enzyme 2 (ACE2) are frequently reported in patients during coronavirus disease 2019 (COVID-19) with evidence for a pathogenic role in severe infection. However, little is known of the prevalence or clinical significance of ACE2 autoantibodies in late convalescence or following COVID-19 vaccination. In this study, we measured ACE2 autoantibodies in a cohort of 182 COVID-19 convalescent patients, 186 COVID-19 vaccine recipients, and 43 adolescents with post-mRNA vaccine myopericarditis using two ACE2 enzymatic immunoassays (EIAs). ACE2 IgM autoantibody EIA median optical densities (ODs) were lower in convalescent patients than pre-COVID-19 control samples with only 2/182 (1.1%) convalescents testing positive. Similarly, only 3/182 (1.6%) convalescent patients tested positive for ACE2 IgG, but patients with history of moderate-severe COVID-19 tended to have significantly higher median ODs than controls and mild COVID-19 patients. In contrast, ACE2 IgG antibodies were detected in 10/186 (5.4%) COVID-19 vaccine recipients after two doses of vaccination. Median ACE2 IgG EIA ODs of vaccine recipients were higher than controls irrespective of the vaccine platform used (inactivated or mRNA). ACE2 IgG ODs were not correlated with surrogate neutralizing antibody levels in vaccine recipients. ACE2 IgG levels peaked at day 56 post-first dose and declined within 12 months to baseline levels in vaccine recipients. Presence of ACE2 antibodies was not associated with adverse events following immunization including myopericarditis. One convalescent patient with ACE2 IgG developed Guillain−Barre syndrome, but causality was not established. ACE2 autoantibodies are observed in COVID-19 vaccine recipients and convalescent patients, but are likely innocuous. |
Persistent Identifier | http://hdl.handle.net/10722/348626 |
ISSN | 2023 Impact Factor: 6.8 2023 SCImago Journal Rankings: 1.560 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tsoi, James Yiu Hung | - |
dc.contributor.author | Cai, Jianpiao | - |
dc.contributor.author | Situ, Jianwen | - |
dc.contributor.author | Lam, Winston Jim | - |
dc.contributor.author | Shun, Estie Hon Kiu | - |
dc.contributor.author | Leung, Joy Ka Yi | - |
dc.contributor.author | Chen, Lin Lei | - |
dc.contributor.author | Chan, Brian Pui Chun | - |
dc.contributor.author | Yeung, Man Lung | - |
dc.contributor.author | Li, Xin | - |
dc.contributor.author | Chan, Kwok Hung | - |
dc.contributor.author | Wong, Joshua Sung Chih | - |
dc.contributor.author | Kwan, Mike Yat Wah | - |
dc.contributor.author | To, Kelvin Kai Wang | - |
dc.contributor.author | Yuen, Kwok Yung | - |
dc.contributor.author | Sridhar, Siddharth | - |
dc.date.accessioned | 2024-10-11T00:30:55Z | - |
dc.date.available | 2024-10-11T00:30:55Z | - |
dc.date.issued | 2023-12-15 | - |
dc.identifier.citation | Journal of Medical Virology, 2023, v. 95, n. 12 | - |
dc.identifier.issn | 0146-6615 | - |
dc.identifier.uri | http://hdl.handle.net/10722/348626 | - |
dc.description.abstract | Autoantibodies against angiotensin-converting enzyme 2 (ACE2) are frequently reported in patients during coronavirus disease 2019 (COVID-19) with evidence for a pathogenic role in severe infection. However, little is known of the prevalence or clinical significance of ACE2 autoantibodies in late convalescence or following COVID-19 vaccination. In this study, we measured ACE2 autoantibodies in a cohort of 182 COVID-19 convalescent patients, 186 COVID-19 vaccine recipients, and 43 adolescents with post-mRNA vaccine myopericarditis using two ACE2 enzymatic immunoassays (EIAs). ACE2 IgM autoantibody EIA median optical densities (ODs) were lower in convalescent patients than pre-COVID-19 control samples with only 2/182 (1.1%) convalescents testing positive. Similarly, only 3/182 (1.6%) convalescent patients tested positive for ACE2 IgG, but patients with history of moderate-severe COVID-19 tended to have significantly higher median ODs than controls and mild COVID-19 patients. In contrast, ACE2 IgG antibodies were detected in 10/186 (5.4%) COVID-19 vaccine recipients after two doses of vaccination. Median ACE2 IgG EIA ODs of vaccine recipients were higher than controls irrespective of the vaccine platform used (inactivated or mRNA). ACE2 IgG ODs were not correlated with surrogate neutralizing antibody levels in vaccine recipients. ACE2 IgG levels peaked at day 56 post-first dose and declined within 12 months to baseline levels in vaccine recipients. Presence of ACE2 antibodies was not associated with adverse events following immunization including myopericarditis. One convalescent patient with ACE2 IgG developed Guillain−Barre syndrome, but causality was not established. ACE2 autoantibodies are observed in COVID-19 vaccine recipients and convalescent patients, but are likely innocuous. | - |
dc.language | eng | - |
dc.publisher | Wiley Periodicals | - |
dc.relation.ispartof | Journal of Medical Virology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | ACE2 | - |
dc.subject | autoantibody | - |
dc.subject | COVID-19 | - |
dc.subject | COVID-19 vaccine | - |
dc.subject | enzymatic immunoassay | - |
dc.subject | SARS-CoV-2 | - |
dc.title | Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1002/jmv.29313 | - |
dc.identifier.pmid | 38100626 | - |
dc.identifier.scopus | eid_2-s2.0-85179735602 | - |
dc.identifier.volume | 95 | - |
dc.identifier.issue | 12 | - |
dc.identifier.eissn | 1096-9071 | - |
dc.identifier.issnl | 0146-6615 | - |